Briacell Therapeutics Corp
NASDAQ:BCTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
There is not enough data to reliably calculate the intrinsic value for Briacell Therapeutics Corp.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Briacell Therapeutics Does
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer.
- Headquarters
- Canada CA
- Employees
- 16
- IPO date
- Oct 12, 2006